Gastrointestinal disorders and dabigatran

Scandinavian Journal of Gastroenterology

Volumn 48, Issue 1, 2013, Pages 9-16

  Hoffman, Arthur ^a   Galle, P R ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Gastroduodenal clinical; General

Indexed keywords

ANTIVITAMIN K; DABIGATRAN; DABIGATRAN ETEXILATE; TARTARIC ACID; WARFARIN;

CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; HUMAN; NAUSEA; NONHUMAN; PAIN; PRIORITY JOURNAL; REVIEW; URINARY EXCRETION; VENOUS THROMBOEMBOLISM; VOMITING;

ANTICOAGULANTS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; DYSPEPSIA; HUMANS; PYRIDINES; STROKE;

EID: 84871381443     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2012.706825     Document Type: Review

References (43)

1. Gums JG. Place of dabigatran in contemporary pharmacotherapy. Pharmacotherapy 2011;31:335-7.
2. Nutescu E, Chuatrisorn I, Hellenbart E. Drug and dietary interactions of warfarin and novel oral anticoagulants: An update. J Thromb Thrombolysis 2011;[Epub ahead of print].
3. Marongiu F, Tosetto A, Palareti G. Special indications for vitamin K antagonists: A review. Intern Emerg Med 2011; [Epub ahead of print].
4. European Association for Cardio-Thoracic Surgery European Heart Rhythm Association.
5. European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31:2369-429.
6. Galanis T, Thomson L, Palladino M, Merli GJ. New oral anticoagulants. J Thromb Thrombolysis 2011;[Epub ahead of print].
7. Faltas B. A new anticoagulant for a new era: Review of recent data on dabigatran etexilate. Clin Adv Hematol Oncol 2010; 8:697-702.
8. Garnock-Jones KP. Dabigatran etexilate: A review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation. Am J Cardiovasc Drugs 2011;11: 57-72.
9. Edwards D. Dabigatran v warfarin. Compare with higher standard. BMJ 2010;341.
10. Eisert WG, Hauel N, Stangier J, Wienen W, Clemens A, van Ryn J. Dabigatran: An oral novel potent reversible nonpeptide inhibitor of thrombin. Arterioscler Thromb Vasc Biol 2010;30:1885-9.
11. Eriksson BI, Quinlan DJ, Eikelboom JW. Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism. Annu Rev Med 2011;62:41-57.
12. Iqbal Z, Cohen M. Emerging antithrombotic agents: what does the intensivist need to know? Curr Opin Crit Care 2010; 16:419-25.
13. Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 2008;36:386-99. (Pubitemid 351185753)
14. Stangier J, Eriksson BI, Dahl OE, Ahnfelt L, Nehmiz G, Stähle H, et al. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol 2005;45:555-63. (Pubitemid 40562946)
15. Lee CJ, Ansell JE. Direct thrombin inhibitors. Br J Clin Pharmacol 2011.
16. Stangier J, Clemens A. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost 2009;15 (Suppl 1):9S-16S.
17. Stangier J, Rathgen K, Stähle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: An open-label, parallel-group, single-centre study. Clin Pharmacokinet 2010;49:259-68.
18. van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, et al. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010;103:1116-27.
19. van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, et al. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010;103:1116-27.
20. Verma AK. Dabigatran etexilate: A new thrombin inhibitor. Med J Aust 2010;192:407-12.
21. Eisert WG, Hauel N, Stangier J, Wienen W, Clemens A, van Ryn J. Dabigatran: An oral novel potent reversible nonpeptide inhibitor of thrombin. Arterioscler Thromb Vasc Biol 2010;30:1885-9.
22. Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 2008;36:386-99. (Pubitemid 351185753)
23. Stangier J, Stähle H, Rathgen K, Fuhr R. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet 2008;47:47-59. (Pubitemid 350260888)
24. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51.
25. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009;361:2342-52.
26. Ezekowitz MD, Wallentin L, Connolly SJ, Parekh A, Chernick MR, Pogue J, RE-LY Steering Committee and Investigators. Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation. Circulation 2010;122:2246-53.
27. Piccini JP, Lopes RD, Mahaffey KW. Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation. Curr Opin Cardiol 2010;25:312-20.
28. Ford AC, Marwaha A, Lim A, Moayyedi P. What is the prevalence of clinically significant endoscopic findings in subjects with dyspepsia? Systematic review and meta-analysis. Clin Gastroenterol Hepatol 2010;8:830-7.
29. Talley NJ, Vakil N; Practice Parameters Committee of the American College of Gastroenterology. Guidelines for the management of dyspepsia. Am J Gastroenterol 2005;100: 2324-37.
30. Bytzer P. Dyspepsia as an adverse effect of drugs. Best Pract Res Clin Gastroenterol 2010;24:109-20.
31. Pearson RK, Hauben M, Goldsmith DI, Gould AL, Madigan D, O'Hara DJ, et al. Influence of the MedDRA hierarchy on pharmacovigilance data mining results. Int J Med Inform 2009;78:e97-e103.
32. Mozzicato P. Standardised MedDRA queries: Their role in signal detection. Drug Saf 2007;30:617-19. (Pubitemid 47037323)
33. Kang JY. Systematic review: Geographical and ethnic differences in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2004;20:705-17. (Pubitemid 39319226)
34. Jung HK. Epidemiology of gastroesophageal reflux disease in Asia: A systematic review. J Neurogastroenterol Motil 2011; 17:14-27.
35. Hankey GJ, Eikelboom JW. Dabigatran etexilate: A new oral thrombin inhibitor. Circulation 2011;123:1436-50.
36. Emmett M. Recurrent tartaric acid acidosis? Kidney Int 2011;79:258-9.
37. Spiller GA, Story JA, Furumoto EJ, Chezem JC, Spiller M. Effect of tartaric acid and dietary fibre from sun-dried raisins on colonic function and on bile acid and volatile fatty acid excretion in healthy adults. Br J Nutr 2003;90:803-7. (Pubitemid 37270763)
38. Spiller GA, Story JA, Lodics TA, Pollack M, Monyan S, Butterfield G, et al. Effect of sun-dried raisins on bile acid excretion, intestinal transit time, and fecal weight: A dose-response study. J Med Food 2003;6:87-91. (Pubitemid 37128468)
39. Krapez-Kordis M, Abram V, Kac M, et al. Determination of organic acids in white wine by RP-HPLC. Food Technol Biotechnol 2001;39:93-9. (Pubitemid 33672771)
40. Greenrod W, Fenech M. The principal phenolic and alcoholic components of wine protect human lymphocytes against hydrogen peroxide- and ionizing radiationinduced DNA damage in vitro. Mutagenesis 2003;18: 119-26. (Pubitemid 36336527)
41. Garrido-Delgado R, López-Vidal S, Arce L, Valcárcel M. Differentiation and identification of white wine varieties by using electropherogram fingerprints obtained with CE. J Sep Sci 2009;32:3809-16.
42. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999;340:1888-99; No abstract available. Erratum in: N Engl J Med 1999 Aug 12;341:548. (Pubitemid 29272670)
43. Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: An analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011; [Epub ahead of print].